The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Illuccix, Telix Pharmaceuticals’ prostate cancer imaging kit. The sNDA will enable the use of Illuccix to aid in the selection of patients with metastatic prostate cancer for whom radioligand therapy is indicated. After radiolabeling with gallium (68Ga), Illuccix is used for the preparation of 68Ga gozetotide injections for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer who have suspected metastasis and are suitable for initial definitive therapy, or who have suspected recurrence ...
RLT-PSMA
Advertisement
Latest News
Scott Tagawa, MD, MS, FACP, shares what needs to happen for radionuclide therapy to make its way into the community setting.
Scott Tagawa, MD, MS, FACP, highlights what clinicians must know prior to recommending Lutetium-177–PSMA-617 to patients.
Dr. Ulaner highlights the line(s) of therapy in which novel RLT-PSMA agents are being developed.
Dr. Ulaner explains the data that led to the FDA approval of 177Lu-PSMA-617 and the safety profile of this drug.
Moffitt Cancer Center developed the first PRO measure for patients receiving RNT to guide treatment and improve QoC.
While PSMA-RLT is typically used during later disease stages, patients in earlier disease stages may benefit as well.
Advertisement
Expert Interviews
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
Andrea Necchi, MD, speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
Advertisement
Roundtables
The panel discusses lutetium-177-PSMA for the treatment of advanced prostate cancer and reviews the VISION trial.
Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.
Advertisement
